Decker Dg
About
In The Last Decade
Decker Dg
22 papers receiving 530 citations
Peers
Comparison fields: 5 of 67
- Reproductive Medicine 375
- Obstetrics and Gynecology 191
- Surgery 154
- Oncology 136
- Genetics 91
Countries citing papers authored by Decker Dg
This map shows the geographic impact of Decker Dg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Decker Dg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Decker Dg more than expected).
Fields of papers citing papers by Decker Dg
This network shows the impact of papers produced by Decker Dg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Decker Dg. The network helps show where Decker Dg may publish in the future.
Co-authorship network of co-authors of Decker Dg
This figure shows the co-authorship network connecting the top 25 collaborators of Decker Dg. A scholar is included among the top collaborators of Decker Dg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Decker Dg. Decker Dg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 12 | |
| 2 | Cyclophosphamide plus cis-platinum in combination: treatment program for stage III or IV ovarian carcinoma. | 110 |
| 3 | Concomitant phase II studies of pyrazofurin and razoxane in alkylating agent-resistant cases of epithelial ovarian carcinoma. | 7 |
| 4 | Medroxyprogesterone acetate for the treatment of metastatic and recurrent ovarian carcinoma. | 30 |
| 5 | Prognostic importance of histologic grading in ovarian carcinoma. | 30 |
| 6 | Histology of epithelial tumors of the ovary: clinical usefulness and prognostic significance of the histologic classification and grading. | 50 |
| 7 | Cancer metastatic to the ovary: factors influencing survival. | 108 |
| 8 | 6-Dehydro-6,17 alpha-dimethylprogesterone (NSC-123018) for the treatment of metastatic and recurrent ovarian carcinoma. | 12 |
| 9 | The diagnosis and management of ovarian cancer. | 5 |
| 10 | Proceedings: Grading of gynecologic malignancy: epithelial ovarian cancer. | 9 |
| 11 | Clear-cell adenocarcinoma of the cervix after maternal treatment with synthetic estrogens. | 33 |
| 12 | Advanced ovarian cancer: therapy with radiation and cyclophosphamide in a random series. | 15 |
| 13 | Postmenopausal bleeding from atrophic endometrium. | 6 |
| 14 | Chemotherapy of squamous cell carcinoma of the cervix, vagina, and vulva. | 10 |
| 15 | Arteriovenous fistulas of the female pelvis. A diagnostic problem. | 28 |
| 16 | [Cyclophosphamide as adjuvant treatment of the advanced ovarian carcinoma]. | 1 |
| 17 | Survival in invasive carcinoma of the cervix five to ten years after radiation therapy. | 6 |
| 18 | Late results of radiation therapy for cancer of the cervical stump. | 5 |
| 19 | The intensive divided-dose irradiation therapy of carcinoma of the uterine cervix: rationale and late results. | 4 |
| 20 | Recurrent carcinoma of the cervix in a patient having double cervix, uterus and vagina. | 2 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.